Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

05_01 Woo ABA_2019 Section of Litigation

ABA: 2019 Section of Litigation & Solo, Small Firm and General Practice Division CLE Conference

ABA: 2019 Section of Litigation & Solo, Small Firm and General Practice Division CLE Conference

Summary

Speakers

Darryl M. Woo

Related Content

The Case for Keeping AI Disputes Out of Court

Post-Award Considerations and a Look to the Future (IAM)

Determining When Engineered Biologics May Be Patentable (Law360)

Can AI-Discovered Drugs Be Patented?

AI Drug Discovery Tests the Limits of Patent Law

Watch Out Section 101, the USPTO Has a New Sheriff in Town

Northern District of California Judge Rules That Meta’s Training of AI Models Is Fair Use

District Court Issues AI Fair Use Decision: Using Copyrighted Works to Train AI Models Is Fair Use, but Using Pirated Copies to Build a Central Library Is Not

Goodwin Advises Hansoh Pharma on Intellectual Property Aspects for License Collaboration and Strategic Investment With Avere for $120 Million Upfront and Up to $2.18 Billion in Milestone Payments

Goodwin Guides IP for Pharmakon on Up to $200 Million Financing for Kestra Medical Technologies

Competition-IP Interface: Transactions, Collaboration, and Unilateral Conduct (Practical Law)

Goodwin Advises Pharmakon Advisors on Intellectual Property Aspects for CHF 250 Million ($310 Million USD) Loan to Idorsia Pharmaceuticals Ltd

Chambers USA 2026 Recognizes a Record Number of Goodwin Practices and Lawyers for Exceptional Client Service

Goodwin Advises Pharmakon Advisors on Intellectual Property Aspects for $500 Million Debt Facility With Mineralys Therapeutics

Goodwin Advises Marshall Wace on Co-Leading Achieve Life Sciences’ $354 Million Private Placement

How Geneticist Damir Musaev Became a PhD at Yale University and Landed at a Top Law Firm With $2 Billion in Revenue (limon.kg)

Intellectual Property

Patent Litigation